CD274 and cancer: Huang et al. designed a novel cancer vaccine (meAAV) in which adeno-associated viruses were optimized to include tumor neoantigens, TLR9 inhibitory fragments, PD-1 traps, and PD-L1 miRNA (Huang et al., 2023).